Tessa Brabander
About
Tessa Brabander is a scholar working on Oncology, Epidemiology and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Tessa Brabander has authored 54 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 33 papers in Epidemiology and 23 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Tessa Brabander's work include Neuroendocrine Tumor Research Advances (33 papers), Lung Cancer Research Studies (24 papers) and Radiopharmaceutical Chemistry and Applications (20 papers). Tessa Brabander is often cited by papers focused on Neuroendocrine Tumor Research Advances (33 papers), Lung Cancer Research Studies (24 papers) and Radiopharmaceutical Chemistry and Applications (20 papers). Tessa Brabander collaborates with scholars based in Netherlands, Germany and Canada. Tessa Brabander's co-authors include Wouter W. de Herder, Richard A. Feelders, Jaap J.M. Teunissen, Boen L.R. Kam, Johannes Hofland, Dik J. Kwekkeboom, Wouter A. van der Zwan, Casper H.J. van Eijck, Gaston J H Franssen and Eric P. Krenning and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Clinical Endocrinology & Metabolism and Clinical Cancer Research.
In The Last Decade
Tessa Brabander
53 papers receiving 1.5k citations
Hit Papers
Peers
Tessa Brabander
Stefano Severi Italy
Amir Sabet Germany
Ulrike Garske‐Román Sweden
Silvia M. Baio Italy
Dorota Kendler Austria
Nicolas Marincek Switzerland
Vincenzo Allegri Italy
Raffaella Barone Netherlands
Ulrike Garske Sweden
Ina Binse Germany
Citations per year, relative to Tessa Brabander Tessa Brabander (= 1×)
peers
Stefano Severi
Countries citing papers authored by Tessa Brabander
Since
Specialization
Citations
This map shows the geographic impact of Tessa Brabander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tessa Brabander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tessa Brabander more than expected).
Fields of papers citing papers by Tessa Brabander
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Tessa Brabander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tessa Brabander. The network helps show where Tessa Brabander may publish in the future.
Co-authorship network of co-authors of Tessa Brabander
This figure shows the co-authorship network connecting the top 25 collaborators of Tessa Brabander. A scholar is included among the top collaborators of Tessa Brabander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tessa Brabander. Tessa Brabander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bruchertseifer, Frank, Aliyah Morgenstern, Yann Seimbille, et al.. (2025). Ac-225 radiochemistry through the lens of [225Ac]Ac-DOTA-TATE. EJNMMI Radiopharmacy and Chemistry. 10(1). 9–9.
2.
Lussanet, Quido G. de, Erik de Blois, Stijn L.W. Koolen, et al.. (2025). First real-world clinical experience with [177Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria. European Journal of Nuclear Medicine and Molecular Imaging. 52(6). 2034–2040.
3.
Lussanet, Quido G. de, et al.. (2024). How to design a theranostic trial?. SHILAP Revista de lepidopterología. 4(1). e230045–e230045.
4.
Segbers, Marcel, Niven Mehra, Paul Hamberg, et al.. (2023). 68Ga-PSMA PET/CT for Response Evaluation of223Ra Treatment in Metastatic Prostate Cancer. Journal of Nuclear Medicine. 64(10). 1556–1562.
5.
Hofland, Johannes, Tessa Brabander, Frederik A. Verburg, Richard A. Feelders, & Wouter W. de Herder. (2022). Peptide Receptor Radionuclide Therapy. The Journal of Clinical Endocrinology & Metabolism. 107(12). 3199–3208.
6.
Blois, Erik de, et al.. (2022). Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer. Pharmaceutics. 14(10). 2166–2166.
7.
Brouwers, Adrienne H., Derk Jan A. de Groot, Johannes Hofland, et al.. (2022). Comparison of [18F]DOPA and [68Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy. SHILAP Revista de lepidopterología. 6(1). 12–12.
8.
Eijck, Casper H.J. van, Marie‐Louise F. van Velthuysen, Els J.�M. Nieveen van Dijkum, et al.. (2022). Induction therapy with 177Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients. European Journal of Nuclear Medicine and Molecular Imaging. 49(9). 3203–3214.
9.
Brabander, Tessa, Margot Tesselaar, Johannes Hofland, et al.. (2022). Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy. EJNMMI Research. 12(1). 7–7.
10.
Zandee, Wouter T., Tessa Brabander, Anela Blažević, et al.. (2021). Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome. The Journal of Clinical Endocrinology & Metabolism. 106(9). e3665–e3672.
11.
Khan, Mohid S., Elaine Stamp, Cormac Sammon, et al.. (2021). Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours. SHILAP Revista de lepidopterología. 16. 5–13.
12.
Segbers, Marcel, Frank Bruchertseifer, Aliyah Morgenstern, et al.. (2021). Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC. Pharmaceutics. 13(5). 715–715.
13.
Meijer, Dennie, Pim J. van Leeuwen, Sebastiaan Remmers, et al.. (2020). Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer. The Journal of Urology. 205(4). 1100–1109.
14.
Brabander, Tessa, Francien H. van Nederveen, Marie‐Louise F. van Velthuysen, et al.. (2019). Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls. BMC Cancer. 19(1). 325–325.
15.
Wyld, David, Tessa Brabander, Jaap J.M. Teunissen, et al.. (2018). A randomized controlled study comparing treatment of gastro-entero-pancreatic neuroendocrine tumors (GEPNET) with 177Lu-DOTATATE alone and in combination with capecitabine. Neuroendocrinology. 106. 261–261.
16.
Zwan, Wouter A. van der, Tessa Brabander, Boen L.R. Kam, et al.. (2018). Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging. 46(3). 704–717.
17.
Brabander, Tessa, Wouter A. van der Zwan, Jaap J.M. Teunissen, et al.. (2017). Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clinical Cancer Research. 23(16). 4617–4624.
18.
Brabander, Tessa, Wouter A. van der Zwan, Jaap J.M. Teunissen, et al.. (2017). Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. Endocrine Related Cancer. 24(5). 243–251.
19.
Vliet, Esther I. van, Casper H.J. van Eijck, Ronald R. de Krijger, et al.. (2015). Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate. Journal of Nuclear Medicine. 56(11). 1647–1653.
20.
Brabander, Tessa, Dik J. Kwekkeboom, Richard A. Feelders, Adrienne H. Brouwers, & Jaap J.M. Teunissen. (2015). Nuclear Medicine Imaging of Neuroendocrine Tumors. Frontiers of hormone research. 44. 73–87.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Stefano Severi Breakdown of academic impact, for papers by Amir Sabet Breakdown of academic impact, for papers by Ulrike Garske‐Román Breakdown of academic impact, for papers by Silvia M. Baio Breakdown of academic impact, for papers by Dorota Kendler Breakdown of academic impact, for papers by Nicolas Marincek Breakdown of academic impact, for papers by Vincenzo Allegri Breakdown of academic impact, for papers by Raffaella Barone Breakdown of academic impact, for papers by Ulrike Garske Breakdown of academic impact, for papers by Ina Binse